lobbying_activities: 2614891

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2614891 209395a0-9c94-43de-ae10-a59fd17ac210 Q1 SWISHER INTERNATIONAL, INC., F/K/A SI GROUP CLIENT SERVICES 401105162 SWISHER INTERNATIONAL, INC., F/K/A SI GROUP CLIENT SERVICES 2021 first_quarter TOB Outreach and monitoring related to the tobacco industry. Outreach and monitoring related to federal COVID-19 relief and stimulus legislation. Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees. Monitored the following: -Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3). -Federal and legislative action related to the marketing and advertising of tobacco products. -FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act. -FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28) -FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107) -FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661) -FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065) Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   390000 0 0 2021-04-20T13:31:37.513000-04:00